James Marion

James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Tivity Health (NASDAQ:TVTY) Gets Nod of Approval After Restructuring

Tivity Health (NASDAQ:TVTY)

Tivity Health Inc. (NASDAQ:TVTY) received a vote of confidence in their new direction. Chairman Donato Tramuto was named CEO in 2015 and immediately set out to better define the brand and align the business with public perception. They divested themselves of business lines that addressed the entire population health market and directed the company’s efforts at the 50+ age bracket. Investors have responded favorably. TVTY was trading under $10 a year ago and last Friday hit $30.50.

Tivity Health offers the senior community health management programs such as physical and occupational therapy, chiropractic and acupuncture care, and fitness programs. Franklin, TN-based Tivity Health Inc.(NASDAQ:TVTY) uses a proprietary technology platform that produces analytics and predictive modeling to direct customized programs led by Tivity associates. The company’s flagship program is the SilverSneaker fitness program that pays homage to fitness center members that have passed away by spray-painting their sneaker silver and hanging it on the wall so that their memory will be honored.

Tivity Health Inc. (NASDAQ:TVTY) engages the corporate sector by presenting statistics demonstrating that employees with high well-being simply cost less. Tivity claims that the medical costs for high well-being employees are 20% lower than average, while emplyees who report low well-being cost 50% more. Low well-being also hurts performance. One analysis the company points to found an almost $20,000 gap in productivity between surveyed employees with the lowest and highest levels of well-being. Tivity Health (NASDAQ:TVTY) has over 68 million people enrolled in their programs throughout 16,000 fitness and wellness centers including three international facilities.

Sales have improved since 2013 when Tivity Health Inc. (NASDAQ:TVTY) reported a figure of $663.3 million. In 2015 that number improved to $770.6 million. However, the company reported an EPS loss in 2013-2015: -$0.25, -$0.16, and -$0.86. Its cash position is not strong – only $0.02 cash/share which could explain why over 10% of its outstanding shares are held short.

Last week Tivity Health Inc. (NASDAQ:TVTY) reported its Q4 2016 and full year results. For the quarter, revenues were up by 10.1% to $124.9 million. Net income from continuing operations was $12.1 million which represented a YoY increase of 31.2%. For the year, revenues increased from $452.1 million to $501 million and net income from operations rose from $1.18 to $1.47. Importantly 2017 guidance was for revenues in the range of $540 – $550 million. Investors, last Friday, rewarded the company by sending TVTY shares up over 8% on the news.

2/24/2017
Ticker Symbol TVTY
Last Price a/o 4:21 PM EST  $                    29.60
Average Volume                    416,850
Market Cap (mlns)  $              1,060.00
Sales (mlns) $562.30
Shares Outstanding (mlns) 35.65
Share Float (mlns) 35.65
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 10.86%
Short Interest Ratio 9.28
Quarterly Return 28.70%
YTD Return 30.11%
Year Return 171.56%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

Are Investors Cautious about Cempra, Inc. (NASDAQ:CEMP)?

Cempra, Inc. (NASDAQ:CEMP)

Cempra, Inc. (NASDAQ:CEMP) shares are up 40% in the pre-market after the biotech firm announced positive topline results from a phase 3 study of oral fusidic acid in 716 patients with acute bacterial skin and skin structure infections (ABSSSI). Fusidic acid was well tolerated in the study and achieved the primary endpoint. However, what is curious about the Phase 3 study is that fusidic acid has been around since the 1960s when it was developed by Leo Pharma in Denmark.

Korea, Japan, UK, Canada, Europe, Australia, and other countries are said to already have given approval to the product in the form of sodium fusidate. A statement in the press release by William O’Riordan, M.D., chief medical officer of eStudySite, references its long use – “Considering complicated skin infections are one of the most rapidly growing reasons for hospitalizations and emergency department visits each year, the results with fusidic acid in this study are promising, especially for an outpatient population where there is a need for new oral drugs that are effective against MRSA,”

Cempra, Inc. (NASDAQ:CEMP) is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin has been evaluated in two phase 3 clinical trials for community-acquired bacterial pneumonia (CABP). Solithromycin is also in a phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Fusidic acid is Cempra’s second product candidate, which has completed an initial phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI).

In November, shares of Cempra, Inc. (NASDAQ:CEMP) plunged 58% on news that the company had allegedly mislead investors by failing to disclose that its drug candidate Solithromycin posed significant safety risks for hepatotoxicity and that Cempra’s public statements were materially false and misleading at all relevant times. Several law firms initiated class action proceedings and advertised for plaintiffs. Then in early December news hit that the U.S. Food and Drug Administration did not approve its new drug applications for pneumonia drug solithromycin over concerns of hypertotoxicity. Shares again fell over50%.

The last two months of 2016 saw at least seven analysts downgraded the shares to “Hold” or “Underweight”. Cempra, Inc. (NASDAQ:CEMP) shares were trading over $25 in September but now a 40%+ gain in CEMP total a value of just $4.63. It should be noted that there have been reliable reports of heavy insider selling.

2/24/2017
Ticker Symbol CEMP
Last Price a/o 9:37 AM EST  $                      4.60
Average Volume                2,230,000
Market Cap (mlns)  $                  156.37
Sales (mlns) $15.90
Shares Outstanding (mlns) 49.64
Share Float (mlns) 49.64
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 11.89%
Short Interest Ratio 2.64
Quarterly Return -52.63%
YTD Return 12.50%
Year Return -81.36%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

InterCloud Systems Inc. (OTCMKTS:ICLD)

AXT Inc (NASDAQ:AXTI) Beats Estimates

AXT Inc (NASDAQ:AXTI)

AXT Inc. (NASDAQ:AXTI) on Wednesday reported, after-hours, fourth-quarter net income of $2.2 million, after reporting a loss in the same period a year earlier. The Fremont, California-based company said it had profit of $0.06/share which was $0.03 larger than analyst expectations. Revenues were $20.3 million which beat analyst expectations by over $1.2 million but represented a drop of 7.7% for the same quarter last year. For the year, the company reported net income of $5.6 million, or $0.17/share. Revenue was reported as $81.3 million. With less than one hour left in the regular session AXT shares are trading up over 12% at $7.75 on volumes over seven times their normal average daily volume.

AXT Inc. (NASDAQ:AXTI) designs, develops, manufactures and distributes high-performance compound semiconductor substrates. The company’s products are used to fabricate integrated circuits for electronic systems that operate the latest fiber optic communications, wireless communications, and lighting display applications. AXT Inc. has manufacturing facilities in China and investments in 10 subsidiaries & joint ventures in China producing raw materials.

In 2011 AXT Inc. (NASDAQ:AXTI) reported sales of $104.1 million. That number has trended down YoY and in 2015 the company reported sales of $77.5 million. Earnings for shareholders have been negative for the last three years and in 2015 AXT Inc. (NASDAQ:AXTI) posted an EPS loss of $0.08. Of the five firms that follow AXT Inc. (NASDAQ:AXTI), three rate AXTI shares as a “Strong Buy” and two rate the shares as a “Buy”. 

2/23/2017
Ticker Symbol AXTI
Last Price a/o 2:42 PM EST  $                      7.75
Average Volume                    335,230
Market Cap (mlns)  $                  218.52
Sales (mlns) $79.10
Shares Outstanding (mlns) 31.67
Share Float (mlns) 30.73
Shortable Yes
Optionable Yes
Inside Ownership 1.20%
Short Float 30.73%
Short Interest Ratio 0.9
Quarterly Return 35.29%
YTD Return 43.75%
Year Return 159.40%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

 

Depomed, Inc. (NASDAQ:DEPO) Financial Results Push Gains

Depomed, Inc. (NASDAQ:DEPO)

Newark, CA-based Depomed, Inc. (NASDAQ:DEPO) reported a Q4 2016 loss of $44.4 million and shares gained over 8%. The pharmaceutical company also reported Q4 2016 earnings of $0.48 which beat expectations by $0.16. Depomed also beat expectations on revenues – the company reported $123.9 million versus expectations of $122.6 million.

Depomed, Inc. (NASDAQ:DEPO) is a specialty pharmaceutical company focused on products to treat pain and other central nervous system conditions. The company currently markets the following FDA-approved products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Below is a graphic of their product pipeline.

Depomed, Inc. (NASDAQ:DEPO) Sales increased from 2011, when it reported $133 million, to $390.4 million in 2014, but declined in 2015 to $342.7 million. For 2015, the company reported an EPS loss of $1.26 which was down from $2.26 positive figure in 2014. Eight firms follow Depomed, Inc. (NASDAQ:DEPO). Four rate DEPO shares as a “Strng Buy”, three rate the shares as a “Hold”, and one rates DEPO as a “Sell”. Their consensus price target is $22.  

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

2/22/2017
Ticker Symbol DEPO
Last Price a/o 3:46 PM EST  $                    17.18
Average Volume                1,500,000
Market Cap (mlns)  $                  993.50
Sales (mlns) $443.20
Shares Outstanding (mlns) 63
Share Float (mlns) 60.98
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 22.21%
Short Interest Ratio 9.01
Quarterly Return -23.26%
YTD Return -12.49%
Year Return -8.58%

 

Lantheus Holdings, Inc. (NASDAQ:LNTH) Two Reason the Shares Rocketed

Lantheus Holdings, Inc. (NASDAQ:LNTH)

Massachusetts- based Lantheus Holdings, Inc. (NASDAQ:LNTH) shares are up over 30% on volumes over 6 times their pro-rated daily averages. Today the company released its 4th quarter and fiscal year financials as well as terms of a partnership between itself and GE Healthcare (NYSE:GE).

Lantheus Holdings, Inc. (NASDAQ:LNTH) revenues for Q4 2016 totaled $74.4 million, compared to $71.2 million for Q4 2015. For the full year 2016, worldwide revenues totaled $301.9 million, compared to $293.5 in 2015, exceeding 2016 guidance of $296 – $299 million. Revenue results were driven by growth in sales of DEFINITY® and TechneLite®, partially offset by price concessions for Xenon as part of the Company’s nuclear products contracting strategy. Also impacting revenues were the divestitures of Lantheus’ Canadian and Australian radio-pharmacy businesses. Lantheus Holdings, Inc. (NASDAQ:LNTH) anticipates worldwide revenues for full year 2017 of approximately $312 – $317 million, compared to $301.9 million in 2016. For the first quarter of 2017, the company expects worldwide revenues in the range of $77 – $80 million.

Also today, Lantheus Holdings, Inc. (NASDAQ:LNTH) and GE Healthcare (NYSE:GE) signed a term sheet for the continued development of flurpiridaz F18, an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease. According to the term sheet, GE will fund the second Phase 3 study, global regulatory submissions and commercialization activities. Lantheus will collaborate in develop and commercialization through a joint steering committee while maintaining an option to co-promote flurpiridaz in the U.S. Lantheus will receive $5M upfront and possibly up to $60M in milestones, tiered double-digit royalties in the U.S., and single-digit royalties ex-U.S. The deal should close in Q2.

Lantheus Holdings, Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care. Their products assist physicians in the diagnosis of conditions affecting the heart, brain, lungs, and other organs using echocardiography and nuclear imaging.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance.

2/22/2017
Ticker Symbol LNTH
Last Price a/o 2:16 PM EST  $                      2.82
Average Volume                    293,500
Market Cap (mlns)  $                  328.84
Sales (mlns) $298.70
Shares Outstanding (mlns) 35.17
Share Float (mlns) 35.17
Shortable Yes
Optionable Yes
Inside Ownership 2.80%
Short Float 2.80%
Short Interest Ratio 3.36
Quarterly Return 1.08%
YTD Return 8.72%
Year Return 358.33%

Community Health Systems, Inc. (NYSE:CYH) Stuns Analysts

Community Health Systems, Inc. (NYSE:CYH)

Shares of Community Health Systems, Inc. (NYSE:CYH) are up over 30% on the back of the company’s earnings release and an analyst upgrade. Last Friday CYH shares closed at $6.90, gapped up to open Tuesday trading at $8.60, then reached a high of $9.69 before pulling back to trade around $9 in mid-day trading.

Community Health Systems, Inc. (NYSE:CYH) is an operator of general acute care hospitals. The organization’s affiliates own, operate or lease 158 hospitals in 22 states with approximately 27,000 licensed beds. Based on the unique needs of each community served, these hospitals offer a wide range of diagnostic, medical and surgical services in inpatient and outpatient settings.

Community Health Systems, Inc. (NYSE:CYH) reported adjusted earnings of $0.46/share for Q4 2016 – the street was expecting a figure closer to $0.13. Cash flow from operations was $327 million, compared with $306 million for the same period in 2015, representing a 6.9% increase.

Wayne T. Smith, chairman and chief executive officer of Community Health Systems, Inc., (NYSE:CYH) said, “We concluded the year with solid results in the fourth quarter, including sequential improvements in same-store net operating revenue, adjusted EBITDA and cash flow from operations. Significant progress has been made in our work to divest certain hospitals and other operations, enabling a reduction in our debt and the opportunity to reshape our portfolio into a stronger, more sustainable organization.”

Yesterday, Mizuho Securities upgraded their rating on CYH from “Underperform” to “Neutral” and assigned a price target of $7.50 – about $1 below current trading levels. In all, eighteen firms follow Community Health Systems, Inc., (NYSE:CYH). Two rate the shares as a “Strong Buy”, twelve rate CYH as a “Hold”, and three rate the shares as a “Sell”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

2/21/2017
Ticker Symbol CYH
Last Price a/o 12:07 PM EST  $                      8.93
Average Volume                3,180,000
Market Cap (mlns)  $                  809.50
Sales (mlns) $1,877.00
Shares Outstanding (mlns) 117.32
Share Float (mlns) 109.23
Shortable Yes
Optionable Yes
Inside Ownership 0.20%
Short Float 20.45%
Short Interest Ratio 7.03
Quarterly Return 25.45%
YTD Return 23.43%
Year Return -42.82%

James Marion is a University of Houston student studying Business with a concentration in Finance.

 

 

Energous Corporation (Nasdaq:WATT) Faces Uncertainty with Apple iPhone

Energous Corporation (Nasdaq: WATT)

In January of 2017, the U.S. Patent Office rejected a patent challenge and shares of Energous Corporation (Nasdaq:WATT) rocketed – shortly reaching all-time highs. Today the shares are down over 8% on news that the newest Apple  Inc. (NASDAQ:AAPL) may include wireless recharching in a future iPhone model utilizing a chip solution developed by Broadcom Limited (NASDAQ:AVGO) and dealing a potential blow to future Energous sales.

Energous Corporation (Nasdaq:WATT)is the developer of WattUp®—a wire-free charging technology that Energous hopes will transform the way consumers and industries charge and power electronic devices at home, in the office, in the car and beyond. WattUp is a radio frequency (RF) based charging solution that delivers intelligent, scalable power via radio bands, similar to a Wi-Fi router. WattUp differs from other wireless charging systems in that it delivers power at a distance, to multiple devices – thus resulting in a wire-free experience that saves users from having to plug in their devices.

Energous Corporation (Nasdaq:WATT)closed yesterday at $16.78 and gapped down to open at $15.12 on double the normal daily average volumes. Broadcom Limited (NASDAQ:AVGO), an $83 billion company, ended yesterday at $208.18 and gapped up to open at $209.00 – currently AVGO is trading up about 1% on average volumes.

The unknow factor, and key issue, is Apple’s perception of the risks involved with wireless charging given the issues that Samsung has experienced.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Timken Steel Corporation (NYSE:TMST) Gaps Up on Financial Release

Timken Steel Corporation (NYSE:TMST)

Timken Steel Corporation (NYSE:TMST) closed Thursday at $17.72 and gapped up this morning to open at $19.37 – a 9.4% gain. Volumes are over five times their normal daily averages.

History

Canton, OH Timken Steel Corporation (NYSE:TMST) was founded in 1898 by Henry Timken in St. Louis, MO. The company moved to Canton, OH in 1901 to take advantage of the exploding automobile industry I nearby Detroit, MI.

In 2014 the company changed its corporate structure, the roller bearing producing part of the company was separated from the steel producing part of the company, resulting in two separate companies. The Timken Company continues to manufacture roller bearings, while TimkenSteel produces steel.

The Numbers

Yesterday Timken Steel Corporation (NYSE:TMST) reported fourth-quarter net sales of $214.7 million and a net loss of $67.0 million or minus $1.52 per share. This compares with net sales of $206.6 million and a net loss of $13.8 million or -$0.31/share compared to the same quarter last year. Net sales of $213.8 million and a net loss of $22.2 million or -$0.50/share in the third quarter of 2016. For the full year, net sales were $869.5 million and net loss was $105.5 million or -$2.39 per share. This compares with net sales of $1,106.2 million and a net loss of $45.0 million or -$1.01 per share for full-year 2015.

Timken Steel Corporation (NYSE:TMST) sales and earnings have been declining. In 2011 sales were a reported $1.96 billion – that number fell to $1.11 billion in 2015. In 2011 TMST posted an EPS gain of $3.68 but the following years, with one exception, saw a downtrend and in 2015 TMTS reported a loss of $1.63.

Timken Steel Corporation (NYSE:TMST) is followed by five firms. Two analysts rate the shares as a “Strong Buy”, two rate TMST as a “Hold”, and one rates the shares a “Sell”. Their consensus price target is $17.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/17/2017
Ticker Symbol TMST
Last Price a/o 12:15 AM EST  $                    19.45
Average Volume                    579,000
Market Cap (mlns)  $                  789.25
Sales (mlns) $861.40
Shares Outstanding (mlns) 44.54
Share Float (mlns) 35.94
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 15.43%
Short Interest Ratio 9.58
Quarterly Return 29.91%
YTD Return 14.47%
Year Return 132.85%
Smart Sand Inc (NASDAQ:SND)

Southcross Energy Partners, L.P. (NYSE:SXE) Shares Pushing Back Against Analysts

Southcross Energy Partners, L.P. (NYSE:SXE)

Southcross Energy Partners, L.P. (NYSE:SXE) shares are up over 15% on heavy volumes. SXE ended yesterday’s trading at $2.26 but hit a high today of $2.74 – a 20% move. The uptick came in conjunction with volumes nearing 880k thousand shares – average daily volumes are under $200k.

Dallas, TX-based Southcross Energy Partners, L.P. (NYSE:SXE) is a master limited partnership that provides natural gas gathering, processing, treating, compression and transportation services and NGL fractionation and transportation services. It also sources, purchases, transports and sells natural gas and NGLs. Its assets are located in South Texas, Mississippi and Alabama and include two gas processing plants, one fractionation plant and approximately 3,100 miles of pipeline.

Southcross Energy Partners, L.P. (NYSE:SXE) did not fare well in 2015. SXE shares dropped from just over $20 to less than $1. In 2016, four notable financial firms downgraded the shares. However for the past quarter, SXE is up over 66%; for the past year SXE is up 276%; and for year-to-date SXE shares are up over 67%.

On January 9, 2017 Southcross Energy Partners, L.P. (NYSE:SXE) announced a change in leadership. Bruce A. Williamson, currently the Executive Chairman of Holdings and a director of the Southcross general partner, was been named President and Chief Executive Officer of both Holdings and Southcross’ general partner. Mr. Williamson has over 35 years of experience encompassing all facets of the energy value chain with Shell Oil Company, PanEnergy Corporation, Duke Energy, Dynegy, and Cleco Corporation.  He also brings a strong record of accomplishment as a CEO delivering shareholder value through transformation, restructuring, capital allocation, asset transactions and mergers.

Southcross Energy Partners, L.P. (NYSE:SXE) sales dropped from 2014 ($848.5 million) to 2015 ($698.5 million) but are still above levels experienced between 2011 and 2013. Earnings on a per share basis have been negative for the past five years with 2015 reporting a loss of $1.32.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/16/2017
Ticker Symbol SXE
Last Price a/o 3:22 PM EST  $                      2.66
Average Volume                    198,800
Market Cap (mlns)  $                  140.05
Sales (mlns) $554.80
Shares Outstanding (mlns) 61.97
Share Float (mlns) 10.27
Shortable Yes
Optionable Yes
Inside Ownership 0.50%
Short Float 1.40%
Short Interest Ratio 0.72
Quarterly Return 66.18%
YTD Return 67.41%
Year Return 276.67%

Castlight Health, Inc. (NASDAQ:CSLT) Reports Earnings and Talks About Acquisiton

Castlight Health, Inc. (NASDAQ:CSLT)

Castlight Health, Inc. (NASDAQ:CSLT) reported 4th quarter and year end results after regular trading had ended. CSLT hares were up 8% despite reporting a $9.1 million loss for the 4th quarter. The San Francisco, CA-based company reported total revenue for the fourth quarter of 2016 was $29.9 million, an increase of 40% from the fourth quarter of 2015. Gross margin for the fourth quarter of 2016 was 71.9%, compared to a gross margin of 54.7% in the fourth quarter of 2015. Total revenue for 2016 was $101.7 million, an increase of 35% from 2015. Net loss per basic and diluted share was $0.58 in 2016, compared to a net loss per basic and diluted share of $0.85 in 2015.

Castlight Health, Inc. (NASDAQ:CSLT) is reiterating the guidance ranges it provided in its January 4, 2017 press release announcing it’s acquisition of Jiff. The combined company is expected to generate approximately $138 to $142 million in pro forma non-GAAP revenue for the full year 2017. The high-end of this range assumes that Castlight Health, Inc. (NASDAQ:CSLT) contributes $123 million and Jiff contributes $19 million. This would represent pro forma growth of approximately 27% to 30% for the combined company, as compared to pro forma revenue of approximately $109 million for the full year 2016.

Castlight Health, Inc. (NASDAQ:CSLT) provides software products enable employees to make health care decisions, and to communicate and measure their benefit programs. Castlight Health, Inc. (NASDAQ:CSLT) also offers communication and engagement, implementation, and customer support services. It serves customers in a range of industries, including education, manufacturing, retail, technology, and government.

Castlight Health, Inc. (NASDAQ:CSLT) sales have been rising since 2011 when it posted a figure of $$1.9 million and in 2015 the figure improved to $75.3 million. CSLT shareholder have not experienced the same growth. An EPS loss of $0.23 in 2011 increased to a loss of $1.16 before narrowing to a $0.85 loss in 2015. Castlight Health, Inc. (NASDAQ:CSLT) is followed by six firms. Two rate CSLT shares a “Strong Buy” and four rate the shares as a “Hold”. Their consensus price target is $4.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/15/2017
Ticker Symbol CSLT
Last Price a/o 7:32 PM EST  $                      3.40
Average Volume                    364,500
Market Cap (mlns)  $                  331.73
Sales (mlns) $93.10
Shares Outstanding (mlns) 105.31
Share Float (mlns) 48.86
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 6.88%
Short Interest Ratio 9.23
Quarterly Return -36.36%
YTD Return -36.36%
Year Return -5.41%